Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ARQ 234

Drug Profile

ARQ 234

Alternative Names: ARQ-234; DS-234

Latest Information Update: 17 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ducentis BioTherapeutics
  • Class Anti-inflammatories; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action CD200R1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atopic dermatitis

Most Recent Events

  • 17 Mar 2023 Arcutis Biotherapeutics has patents pending for ARQ 234 and other CD200 mutant proteins in Brazil, Canada, Europe, Hong Kong, India, Korea, New Zealand, Singapore
  • 31 Dec 2022 Arcutis Biotherapeutics has patent protection for ARQ 234 and other CD200 mutant protein in USA, Australia, China, Eurasia, Israel, Japan, Mexico, South Korea and South Africa
  • 13 Sep 2022 Ducentis BioTherapeutics has patent protection for CD200 variants in multiple countries including the US and Japan (Ducentis BioTherapeutics website, September 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top